tbuckley/cabot-search huggingface dataset:
A Report on the Natural Duration of Cancer.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Clinical Relevance of Gastrointestinal Endoscopy in Pediatric Patients with Suspected Gastrointestinal Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation
Authors: Thomas Mårtensson, Karin Mellgren, Jacek Toporski, Jonas Matttson, Attila Szakos, Thomas Casswall, Britt Gustafsson
Journal: Blood (2014)
VISMONEO - a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - Patients characteristics
Authors: N. Basset-Seguin, A. Dupuy, P. Saiag, S. Dalac-Rat, B. Guillot, E. Routier, M.T. Leccia, A. Duhamel, X. Mirabel, I. Benbouta, L. Mirakovska, D. Meddour, M. Dib, A. Mahmoudi, P. Guerreschi, L. Mortier
Journal: Annals of Oncology (2016)
Analysis of outcomes and brain metastases (BM) of molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials
Authors: S. Cedres, N. Pardo Aranda, A. Martinez de Castro, A. Navarro Mendivil, A. Martinez Marti, C. Ortiz, F. Racca, M. Vilaro, L. Carbonell, A. Piera, Idela fuente, E. Felip
Journal: Annals of Oncology (2016)
Photo-detection and photo-destruction of oral neoplasia in an animal model
Authors: J. B. Epstein, K. Osann, M. Wilson, J. Pharar, H. Kawakami-Wong, P. W. Smith
Journal: Journal of Clinical Oncology (2008)

17025 Background: Optical techniques for non-invasive early detection, mapping and eradication of oral premalignant lesions (OPLs) and oral squamous cell carcinoma (OSCC) offer many advantages that may benefit patients greatly. Our objective was to assess the utility of photodynamic diagnosis and therapy using toluidine blue (TBO) and light at 633nm for early detection, mapping and selective phtodestruction of neoplastic oral tissues in the hamster cheek pouch carcinogenesis model. Methods: DMBA carcinogenesis was applied to one cheek pouch in 20 hamsters for 6 weeks. After topical application of acetic acid is (1%) and TBO (0.5%), cheek pouches were irradiated using previously identified parameters: 15 J/cm2, 30 J/cm2, 45 J/cm2, and exposure duration of 3 min, 6 min, 9 min and 12 min. After laser irradiation, animals were sacrificed and cheek pouch tissues underwent routine histopathological preparation and evaluation. Using (a) TBO flouorescence and (b) histopahtology, lesion presence was scored as yes/no and lesion delineation was mapped microscopically using a grid and IPLab™ software. Results: Areas of pathology were clearly identified by TBO fluorescence (k=0.85 for delineation). At all laser parameters tested, selective photodestruction was seen, as evidenced by intra-vascular thrombosis and neovascularization in the pathological tissues. Cellular thermal damage was evidenced by atypical cell membranes, vacuolization and loss of inter- and intracellular integrity in the areas of neoplasia. Maximal photodestruction with minimal thermal damage was observed at 30 J/cm2 after 9 min irradiation. Conclusions: Topical toluidine blue may be a useful tool for photodynamic diagnosis and for possible therapy of neoplasia in the oral mucosa No significant financial relationships to disclose.
Adult Patients with Acute Lymphoblastic Leukemia (ALL) and Central Nervous System (CNS) Leukemia at Diagnosis May Attain Durable Complete Remissions (CR). Results from the International ALL Trial (MRC UKALL-XII/ECOG E2993).
Authors: Hillard M. Lazarus, Sue M. Richards, Raj Chopra, Mark R. Litzow, Alan K. Burnett, Peter H. Wiernik, Ian M. Franklin, Martin S. Tallman, G. Buck, Jill Durrant, Jacob M. Rowe, Anthony H. Goldstone
Journal: Blood (2004)
Increased TNF/NGF Receptor Expression on BCP-ALL Blasts Carrying the Prognostically Favorable TEL-AML Rearrangement.
Authors: Anja Troeger, Ludmila Glouchkova, Birgit Ackermann, Gabriele Escherich, Roland Meisel, Hans-Juergen Laws, Helmut Hanenberg, Silja Roettgers, Gritta Janka-Schaub, Arndt Borkhardt, Ulrich Goebel, Dagmar Dilloo
Journal: Blood (2007)
Spatiotemporal Stability of Public Cardiac Arrests
Authors: Derya Demirtas, Steven C. Brooks, Laurie J. Morrison, Timothy C.Y. Chan
Journal: Circulation (2015)

Background: Public access automated external defibrillator (AED) deployment and community cardiopulmonary resuscitation (CPR) programs should target geographical areas with high risk of out-of-hospital cardiac arrest (OHCA). Although these long-term, location-based interventions implicitly assume that the geographical OHCA risk remains stable over time, there is a paucity of evidence to support this assumption.   
Objective: To determine whether geographic OHCA risk is stable over time in a Canadian urban setting.   
Methods: We identified all atraumatic public-location OHCAs in Toronto, Canada from Jan. 2006 – Dec. 2014 and allocated each of them to one of the 140 neighborhoods defined by the City of Toronto. We then calculated the intra-class correlation (ICC) to measure the relative variability of OHCA counts within and between neighbourhoods over time.   
Results: We identified 2506 atraumatic public OHCAs. The figure shows that the average number of public OHCAs in Toronto was 278.4 (±41.4) per year. The highest-risk neighborhood had an average number of 12.9 OHCAs per year and remained the highest-risk neighborhood during six of the nine years. The four lowest-risk neighborhoods each had a rate of 0.1 OHCA per year. The ICC value was 0.67 [95% CI, 0.61 to 0.73], indicating that there was less year-to-year variation within the same neighborhood (i.e., more temporal stability) and more variation between neighborhoods.   
Conclusion: The OHCA rate in Toronto is stable at the neighborhood level over time. High-risk neighborhoods tend to remain high-risk, which supports focusing public health resources in those areas to increase the efficiency of these scarce resources and improve long-term impact.
P13.04 Practice patterns of diagnosis and management of leptomeningeal metastasis in Europe: results from a web-based survey
Authors: E. Le Rhun, M. Weller, R. Soffietti, R. Rudà
Journal: Neuro-Oncology (2016)

AbstractLeptomeningeal metastases are typically a late manifestation of systemic cancer affecting up to 10% of patients with solid tumors. Depending on the pattern of spread within the central nervous system, a broad variety of clinical symptoms and signs may occur, but cranial nerve palsies and multifocal deficits are particularly common. The incidence is highest in lung cancer, malignant melanoma and breast cancer. Survival is a only a few weeks without treatment, but is approximately 10% across the spectrum of patients. The diagnosis is typically triggered by clinical suspicion followed by neuroimaging and cerebrospinal fluid analysis. Management is often individualized and depends on primary tumor and pattern of metastasis, in particular concurrent systemic or solid brain metastases.Here we set out to characterize current practice patterns of diagnosing and treating leptomeningeal metastasis in Europe. To this end, we prepared a web-based survey including multiple choice questions on best practice supplemented by some case vignettes. This survey was sent to members of the European Association of Neuro-Oncology (EANO) and the Brain Tumor Group of the European Organisation for Research and Treatment of Cancer (EORTC) in April 2016.We will present the results of this survey and illustrate patterns of care by profession and country or region. Results from this survey shall inform on the design of future EANO recommendations for the diagnosis and management of leptomeningeal metastasis from solid tumors.
The prognostic role and association of 18F-FDG PET CT and HER2 expression in gastric cancer
Authors: J.S. Park, N. Lee, J.H. Kim, H.S. Park, S.J. Heo, S.H. Beom, H.S. Kim, S.Y. Rha, H.C. Chung, M. Yun, A. Cho, M. Jung
Journal: Annals of Oncology (2016)
melanoma and other skin tumours Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial
Authors: A.M.M. Eggermont, V. Chiarion-Sileni, J.-J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P.A. Ascierto, J.M. Richards, C. Lebbé, V. Ferraresi, M. Smylie, J.S. Weber, C. Taitt, V. de Pril, G. de Schaetzen, S. Suciu, A. Testori
Journal: Annals of Oncology (2016)
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer
Authors: G. Ponti, M. Maccaferri, R. Depenni, M. Mandrioli, G. Pellacani, M. Manfredini, T. Ozben, C. Ruini, E. Iattoni, D. Cerioli, S. Cascinu, A. Tomasi
Journal: Annals of Oncology (2016)
Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML,
Authors: Ajay Abraham, Savitha Varatharajan, Ashok kumar Jayavelu, Shaji R Velayudhan, Rayaz Ahmed, Aby Abraham, Biju George, Mammen Chandy, Alok Srivastava, Vikram Mathews, Poonkuzhali Balasubramanian
Journal: Blood (2011)
Full Dose Vincristine (V) Negatively Impacts Progression Free Survival in Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Treated with Pegylated Doxorubicin, Vincristine, Reduced-Dose Dexamethasone, and Thalidomide (DVd-T).
Authors: R. Suppiah, E. Walker, K. Almhanna, S. Andresen, J. Reed, M. Karam, B. Phillips, M. Kelly, E. Ellis, B. McGowan, M. Hussein
Journal: Blood (2005)
Systematic Review and Meta-Analysis of Randomized Trials Comparing Imatinib 400 Mg/d Vs. Imatinib 800 Mg/d, and Imatinib 400 Mg/d Vs. Second Generation TKIs in Chronic Phase CML-Patients
Authors: Verena Sophia Hoffmann, Joerg Hasford, Ruediger Hehlmann
Journal: Blood (2015)
Length of Stay among Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma:Predictive Factors and Prognostic Effect.
Authors: Anuj Mahindra, Brian Bolwell, Lisa Rybicki, Matt Kalaycio, Ronald Sobecks, Steve Andresen, Brad Pohlman, John Sweetenham, Edward Copelan, Robert Dean
Journal: Blood (2008)
The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia
Authors: Mythri Mudireddy, Daniela Barraco, Curtis A. Hanson, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: American Journal of Hematology (2017)

The 2016 World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (MPN) underscore the prognostically-relevant distinction between essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF). In addition, leukocytosis has been identified as an important prognostic marker in otherwise WHO-defined ET. However, controversy remains regarding the objectivity of morphologic criteria in distinguishing ET from pre-PMF and the precise prognostic cutoff values for leukocytosis. Serum lactate dehydrogenase (LDH) level might be a biologically more accurate measure of leukocyte turnover and a more sensitive marker of pre-PMF, in otherwise WHO-defined ET. In the current study of 183 consecutive patients with WHO-defined ET, the presence of grade 1 bone marrow (BM) fibrosis did not affect presenting clinical or laboratory features; in contrast, increased serum LDH at diagnosis was associated with leukocytosis (p = .002), thrombocytosis (p < .001), palpable splenomegaly (p = .03) and higher international prognostic score (IPSET) (p = .002); serum LDH did not correlate with BM fibrosis, JAK2/CALR/MPL or TET2/ASXL1 mutations. In univariate analysis, risk factors for survival included age ≥60 years (p = .002; HR 10.2, 95% CI 2.3-44.6), male sex (p = .02; HR 3.2, 95% CI 1.2-8.2), leukocyte count ≥15 × 109 /L (p = .007; HR 4.7, 95% CI 1.5-14.6), and increased serum LDH (p = .002; HR 3.7, 95% CI 1.5-9.1), but not BM fibrosis (p = .17). In multivariable analysis, age, sex and serum LDH remained significant; serum LDH also remained significant, in the context of IPSET (p = .003) and in patients with leukocytosis (p = .003). We conclude that serum LDH level carries an independent prognostic value for survival in ET and might represent a biologically more accurate surrogate for leukocytosis.
FOLFOX or XELOX as adjuvant therapy after curative resection of metastatic or relapsed colorectal cancer
Authors: Kentaro Sawada, Yoshito Komatsu, Satoshi Yuki, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Tetsuhito Muranaka, Atsusi Ishiguro, Kazuteru Hatanaka, Naohide Sasaki, Takuto Miyagishima, Naoya Sakamoto
Journal: Annals of Oncology (2016)
Donor-Derived B Cells Produce Potent AML-Specific Antibodies That Recognize Novel Tumor-Specific Antigens and Mediate Graft-Versus-Leukemia Immunity
Authors: Marijn Aletta Gillissen, Martijn Kedde, Etsuko Yasuda, Sophie E. Levie, Arjen Q. Bakker, Yvonne B. Claassen, Martino Bohne, Dave Speijer, Daisy I. Picavet, Jan Stap, Marinus H. J. van Oers, Tim Beaumont, Pauline M. van Helden, Hergen Spits, Mette D. Hazenberg
Journal: Blood (2015)
NIMG-56. PATTERNS FROM DYNAMIC VESSEL SIZE IMAGING OF ARTERIAL AND VENOUS PERFUSION CORRELATES WITH AGGRESSIVENESS AND STRATIFIES 1p19q CO-DELETED FROM NON-CODELETED LOW-GRADE GLIOMAS
Authors: Kevin Leu, Timothy Cloughesy, Linda Liau, Phioanh Nghiemphu, Albert Lai, Whitney Pope, Benjamin Ellingson
Journal: Neuro-Oncology (2016)

Glioma growth is highly dependent on angiogenesis, and MR perfusion imaging has been an active area research for identifying pathophysiologic vascular proliferation. One imaging technique showing is vessel size imaging (VSI), which measures the microvascular vessel caliber in tumors through a combination of the ratio of the gradient echo and spin echo contrast susceptibility (DR2*/DR2) and the apparent diffusion coefficient. In this study, we describe a method where we can compute VSI as the bolus passes through various vascular structures, allowing quantification of vascular heterogeneity of arteries, capillaries, and veins within the tumors. Eleven pre-surgical glioma patients (4 grade II, 6 grade III, 1 grade IV; 6 oligodendrogliomas, 5 astrocytomas) participated in this study, none of whom were on treatment at the time of imaging. VSI, instead of being calculated using the value of maximum DR2*/DR2, was computed over time during the first pass of the bolus. Independent component analysis on the gradient echo was used to determine the time points of arterial, capillary, and venous time points. Voxels within FLAIR were categorized according to artery, capillary, or vein, based on when the maximum VSI occurred, and a percentage of the tumor was computed for each of the three categories. Across the arterial, capillary, and venous time points, VSI localizes to different areas of the tumor, in a manner that does not simply follow the gradient and spin echo susceptibility curves. The difference between the arterial and venous percentages within the FLAIR lesion was statistically significant, using a non-parametric Spearman test, with respect to differentiating tumor grade (p=0.0346) and oligodendrogliomas versus astrocytomas (p=0.0043), whereas rCBV was only significant with respect to tumor grade (p = 0.0346/p=0.1775). VSI over time provides novel information regarding the vascular heterogeneity within tumors and correlates with tumor grade and glioma subtype.
Impact of human papillomavirus (HPV) E6/E7 gene silencing on the expression of biomarkers that distinguish HPV<sup>+</sup> versus HPV16<sup>-</sup> head and neck squamous cell carcinomas (HNSCC)
Authors: P. Gouveris, T. Rampias, C. Sasaki, A. Psyrri
Journal: Journal of Clinical Oncology (2009)

e17024 Background: Three studies (Pyeon et al, Slebos et al, and Schlecht et al) have identified biomarkers that distinguish HPV + versus HPV - HNSCC using cDNA microarrays. We sought to determine whether the identified biomarker differences are a direct consequence of HPV16 E6 andE7 oncogene expression. Methods: We selected genes that were found to have altered expression in HPV16 + HNSCC compared to HPV16 - . Short hairpin RNAs targeting HPV type 16 E6 and E7 genes were delivered by retrovirus infection to HPV16 + oropharyngeal cancer cell lines 147T and 090. cDNA microarray analysis was performed (slides represented approximately 35000 genes) to determine the transcriptional profile before and after E6/E7 silencing. Results: E6/E7 gene silencing affected the expression of the following genes: RFC4, CDKN2A, MCM6, NASP, EP300, E2F2, PCNA, KLK6, ANGPT1, DNAJCI, PRKCG (Table). Conclusions: Expression of several biomarkers that distinguish HPV16+ from HPV16- HNSCC is regulated by E6/E7 gene expression. Targeting E6/E7 will be an effective therapeutic strategy in HPV16 + HNSCC since alteration of key molecules that increase the malignant potential of these tumors is controlled by E6/E7 expression. [Table: see text] No significant financial relationships to disclose.
Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab
Authors: H. Rugo, A. Barve, C.F. Waller, M. Bronchud, J. Herson, J. Yuan, A. Manikhas, I. Bondarenko, G. Mukhametshina, G. Nemsadze, J.D. Parra, M.L.T. Abesamis-Tiambeng, K. Baramidze, C. Akewanlop, I. Vynnychenko, V. Sriuranpong, G. Mamillapalli, S. Ray, E.P. Yanez Ruiz, E. Pennella
Journal: Annals of Oncology (2016)
Corrigendum: Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions
Authors: Chen Wu, Peter Kraft, Kan Zhai, Jiang Chang, Zhaoming Wang, Yun Li, Zhibin Hu, Zhonghu He, Weihua Jia, Christian C Abnet, Liming Liang, Nan Hu, Xiaoping Miao, Yifeng Zhou, Zhihua Liu, Qimin Zhan, Yu Liu, Yan Qiao, Yuling Zhou, Guangfu Jin, Chuanhai Guo, Changdong Lu, Haijun Yang, Jianhua Fu, Dianke Yu, Neal D Freedman, Ti Ding, Wen Tan, Alisa M Goldstein, Tangchun Wu, Hongbing Shen, Yang Ke, Yixin Zeng, Stephen J Chanock, Philip R Taylor, Dongxin Lin
Journal: Nature Genetics (2014)
Evaluation of Humoral Response to Trivalent Influenza Vaccination in Patients with Non-Hodgkin Lymphoma Previously Treated or Untreated with Chemotherapy.
Authors: Piotr Centkowski, Lidia Brydak, Magdalena Machala, Ewa Kalinka, Maria Blasinska-Morawiec, Joanna Wegrzyn, Aleksander Skotnicki, Irena Federowicz, Jan Walewski, Ilona Seferynska, Przemyslaw Bilinski, Krzysztof Warzocha
Journal: Blood (2004)
P08.68 The Ran signaling pathway is upregulated dependent from glioma grade and radiochemotherapy
Authors: S. Telentschak
Journal: Neuro-Oncology (2016)

AbstractIntroduction:Numerous studies on different non-brain cancers indicate Ran (Ras-related nuclear protein), a key protein in the nucleoplasmic transport during interphase and the regulation of mitotic spindle formation, to be involved in tumorigenesis, cancer progression and tumor cell survival. It further is predictive for poor outcome.Overexpression of Ran has been reported in glioblastoma [GBM] tissue. To further evaluate the role of the Ran signaling pathway in astrocytoma, we measured the expression of its key components Ran, RCC1, RANBP1 and RANBP2 in different types of brain tumor tissue.Materials and Methods:Using qRT-PCR and Western blot analysis the gene and protein expression was analyzed in 80 tissue samples. The tissue subtypes were astrocytomas WHO II°, anaplastic astrocytomas, primary and secondary glioblastomas and tissue samples after recurrence subsequent to radiochemotherapy. Peritumoral brain tissue was used as a control. For PCR analysis at least 10 glioma probes and for Western blot analysis at least 6 glioma probes were used per group.Results:Ran protein overexpression compared to non-neoplastic brain was detected in anaplastic astrocytomas (90%), primary glioblastoma (140%) and secondary glioblastoma (170%). With increasing WHO grade there was an increase of Ran mRNA expression and chemo-radiation therapy led to further enhanced expression in primary and secondary glioblastoma (from 1.36 to 2.25 and from 2.08 to 3.08 arbitrary unites [AU], respectively). There was also an increase in gene expression of RCC1, RANBP1 and RANBP2 analogue to that of Ran: showing a steady increase with higher WHO grading. Correspondingly to Ran, gene expression of RCC1 increased in primary and secondary glioblastoma recurrent after radiochemotherapy from 3.19 to 3.87 AU and from 4.14 to 10.11 AU respectively as well as that of RANBP2 from 2.36 to 5.14 AU and from 2.77 to 4.74 AU respectively.Discussion:Our data clearly show a grade dependent upregulation of key components of the Ran pathway in astrocytomas and a further increase after radiochemotherapy. Therefore, this pathway may represent a future target for glioblastoma therapy.
NOT RECLUSE—A Mnemonic Device to Avoid False Diagnoses of Brown Recluse Spider Bites
Authors: William V. Stoecker, Richard S. Vetter, Jonathan A. Dyer
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Characteristics of gliobastomas (GBM) not resected (only biopsied) homogeneosuly treated with Stupp regimen. Results from the GLIOCAT study
Authors: O. Gallego, A. Estival, M. Martinez-Garcia, E. Pineda, M. Gil, S. Del Barco, J. Marruecos, E. Verger, R. Fuentes, J.M. Velarde, C. Mesía, J. Craven, S. Bague Rosell, C. Quintana, L. PlCarpio De Huerta, E. Granell, B. Gómez, N. García, S. Villà, C. Balana
Journal: Annals of Oncology (2016)
Clinical Significance of Mixed Phenotype in Adult Patients with Philadelphia Chromosome-Positive Acute Leukemia–no Prognostic Impact in the Imatinib Era.
Authors: Hiroaki Shimizu, Akihiko Yokohama, Hiroko Koya, Rumi Shimizu, Nahoko Hatsumi, Satoru Takada, Takayuki Saitoh, Toru Sakura, Shuichi Miyawaki, Hiroshi Handa
Journal: Blood (2012)
CD4+ Effector Memory and Naive T Cells Mediate Graft-Versus-Leukemia Via Direct Recognition of MHCII on Leukemic Cells.
Authors: Hong Zheng, Catherine C. Matte, Srividhya Venkatesan, Britt E. Anderson, Mark J. Shlomchik, Warren D. Shlomchik
Journal: Blood (2005)